13288 Federal Register / Vol. 72, No. 54 / Wednesday, March 21, 2007 / Notices 

the agreement and proposed order or to 

modify in any way their terms. 

By direction of the Commission. 

Donald S. Clark, 

Secretary. 

[FR Doc. 07–1403 Filed 3–20–07; 8:45 am] 

BILLING CODE 6750–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

CDC/HRSA Advisory Committee on 

HIV and STD Prevention and Treatment 

In accordance with section l0(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention and the Health 

Resources and Services Administration 

announce the following meeting of the 

aforementioned committee. 

Times and Dates: 8 a.m. – 5 p.m., May 

7, 2007. 8 a.m. – 12:30 p.m., May 8, 

2007. 

Place: Embassy Suites Hotel Atlanta 

Buckhead, 3285 Peachtree Road, NE., 

Atlanta, Georgia, Telephone 404/261–

7733, Fax 404/262–0522. 

Status: Open to the public, limited 

only by the space available. The meeting 

room will accommodate approximately 

100 people. 

Purpose: This Committee is charged 

with advising the Director, CDC and the 

Administrator, HRSA, regarding 

activities related to prevention and 

control of HIV/AIDS and other STDs, 

the support of health care services to 

persons living with HIV/AIDS, and 

education of health professionals and 

the public about HIV/AIDS and other 

STDs. 

Matters To Be Discussed: Agenda 

items include issues pertaining to (1) 

Priorities for STD Prevention (2) HIV 

Strategic Plan Implementation and (3) 

Leveraging Federal Partnerships for 

HIV/STD Prevention. Agenda items are 

subject to change as priorities dictate. 

Contact Person for More Information: 

Margie Scott-Cseh, Committee 

Management Specialist, National Center 

for HIV, STD, and TB Prevention, 1600 

Clifton Road, NE., Mailstop E–07, 

Atlanta, Georgia 30333. Telephone 404/ 

639–8317, Fax 404/639–8600, e-mail 

zkr7@cdc.gov. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

Notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Dated: March 14, 2007. 

Elaine L. Baker, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. 07–1374 Filed 3–20–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Medical Devices Dispute Resolution 

Panel of the Medical Devices Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Medical Devices 

Dispute Resolution Panel of the Medical 

Devices Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

scientific disputes between the Center 

for Devices and Radiological Health and 

sponsors, applicants, and 

manufacturers. 

Date and Time: The meeting will be 

held on April 19, 2007, from 8:30 a.m. 

to 5:30 p.m. 

Location: Holiday Inn, Ballroom, Two 

Montgomery Village Ave., Gaithersburg, 

MD. 

Contact Person: Nancy Collazo-Braier, 

Center for Devices and Radiological 

Health (HFZ–1), Food and Drug 

Administration, 9200 Corporate Blvd., 

Rockville, MD 20850, 240–276–3959, email: nancy.braier@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014510232. Please call the Information 

Line for up-to-date information on this 

meeting. 

Agenda: The committee will discuss, 

make recommendations, and vote 

regarding a scientific dispute between 

the agency and Cardima Inc. related to 

the not-approvable determination for 

the premarket approval application 

(PMA) for the REVELATION Tx 

Microcatheter with NavAblator Ablation 

System, indicated for the treatment of 

drug refractory paroxysmal atrial 

fibrillation. 

FDA intends to make background 

material available to the public no later 

than 1 business day before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ohrms/ 

dockets/ac/acmenu.htm, click on the 

year 2007 and scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before April 5, 2007. Oral 

presentations from the public will be 

scheduled between approximately 9 

a.m. and 9:30 a.m. and between 

approximately 1:30 p.m. and 2 p.m. 

Those desiring to make formal oral 

presentations should notify the contact 

person and submit a brief statement of 

the general nature of the evidence or 

arguments they wish to present, the 

names and addresses of proposed 

participants, and an indication of the 

approximate time requested to make 

their presentation on or before March 

28, 2007. Time allotted for each 

presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by March 29, 2007. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Ann Marie 

Williams, Conference Management 

Staff, at 301–827–7291, at least 7 days 

in advance of the meeting. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 


jlentini on PROD1PC65 with NOTICES